Skyrizi is a biologic medication that is used to treat moderate to severe plaque psoriasis and Crohn’s disease, as well as active psoriatic arthritis, and plaque psoriasis.
Skyrizi is a treatment that specifically targets the interleukin-23 protein (IL-23), which is one of the key proteins responsible for inflammation. By targeting IL-23, Skyrizi can help decrease excess inflammation that can contribute to symptoms you experience with Crohn’s disease and plaque psoriasis.
Side effects during the treatment of plaque psoriasis and psoriatic arthritis:
Side effects during the treatment of Crohn’s disease at the start of therapy:
Side effects during the treatment of Crohn’s disease during maintenance therapy:
Click here for additional side effects
The recommended induction dosage is to be administered by intravenous infusion over at least one hour.
Induction dosage is done every 4 weeks for three weeks, then maintained by subcutaneous injection on the 12th week and then every 8 weeks after.
Before your infusion, it is important to drink plenty of water and come to your appointment hydrated. Additionally, you must alert us as soon as possible to any changes in your insurance to ensure that we are still an in-network provider for your infusion therapy.